A5066377227- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- T-cell and Retrovirus Studies
- Cancer-related molecular mechanisms research
- Retinal Diseases and Treatments
- Circular RNAs in diseases
- MicroRNA in disease regulation
- Immunodeficiency and Autoimmune Disorders
- Histiocytic Disorders and Treatments
- Glaucoma and retinal disorders
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Gastrointestinal disorders and treatments
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
Universitat de Barcelona
2015-2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2014-2024
Centro de Investigación Biomédica en Red de Cáncer
2017-2024
Hospital Clínic de Barcelona
2013-2023
Spanish Society of Hematology and Hemotherapy
2021
Vall d'Hebron Institut de Recerca
2020
Vall d'Hebron Institute of Oncology
2020
United States Department of Labor
2019
Ministry of Security and Justice
2019
Yale University
2019
The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival patients diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate after treatment lymphoma is unclear.We profiled gene expression in pretreatment biopsy specimens from 181 who received CHOP 233 this disease R-CHOP. A multivariate gene-expression-based survival-predictor model derived a training...
Significance This is a comprehensive whole-genome/whole-exome analysis of mantle cell lymphoma (MCL). We sequenced 29 MCL cases and validated the findings by target sequencing 172 additional tumors. identified recurrent mutations in genes regulating chromatin modification such as NOTCH2 that have major impact on clinical outcome. Additionally, we demonstrated subclonal heterogeneity tumors already at diagnosis modulation mutational architecture progression disease. The identification new...
Plasmablastic lymphoma was initially described as a variant of diffuse large B-cell (DLBCL) involving the oral cavity HIV+ patients and characterized by immunoblastic morphology plasma cell phenotype. However, other lymphomas may exhibit similar morphologic immunophenotypic features. To determine significance plasmablastic differentiation in DLBCL examine heterogeneity with these characteristics, we examined 50 DLBCLs low/absent CD20/CD79a an immunophenotype indicative terminal...
The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this detects most mutations in BC. This information critical as clinicians using other genomic assays indicate alpelisib.Data from 6338 BC was explored across 10 publicly available studies. primary objective evaluate proportion distribution of...
Tumor microenvironment influences the behavior of follicular lymphoma (FL), although specific cell subsets involved are not well known. The aim this study was to determine impact programmed death 1 (PD-1) -positive inhibitory immunoregulatory lymphoid cells in clinicobiologic features and outcome patients with FL.We examined samples from 100 (53 men 47 women; median age, 54 years) at diagnosis, as 32 first relapse, a recently generated monoclonal antibody against PD-1. were quantified using...
Plasmablastic lymphoma (PBL) is an aggressive characterized by a terminally differentiated B-cell phenotype that usually occurs in the immunocompromised or elderly patients. Although clinical and pathologic characteristics of these tumors have been defined, genetic alterations involved their pathogenesis are not well known. In this study, we investigated chromosomal MYC, BCL2, BCL6, MALT1, PAX5, IGH loci using fluorescence situ hybridization 42 PBL 3 extracavitary primary effusion lymphomas....
MYC alterations influence the survival of patients with diffuse large B-cell lymphoma. Most studies have focused on translocations but there is little information regarding impact numerical and protein expression. We analyzed genetic expression MYC, BCL2, BCL6, MALT1 in 219 cases rearrangement occurred as sole abnormality (MYC single-hit) 3% cases, concurrent BCL2 and/or BCL6 rearrangements double/triple-hit) 4%, amplifications 2% gains 19%. single-hit, double/triple-hit amplifications, not...
Both clinical and genomic data independently predict survival treatment response in early-stage HER2-positive breast cancer. Here we present the development validation of a new HER2DX risk score, pathological complete (pCR) both based on 27-gene expression plus feature-based classifier.HER2DX is supervised learning algorithm incorporating tumour size, nodal staging, 4 gene signatures tracking immune infiltration, cell proliferation, luminal differentiation, HER2 amplicon, into single score....
Murine models of Plasmodium falciparum malaria may become crucial tools in drug discovery. Here we show that non-myelodepleted NOD-scid IL2Rgamma(null) mice engrafted with human erythrocytes support an infectious burden up to tenfold higher than supported by beta2microglobulin(null) mice. The new model was validated for discovery and used assess the therapeutic efficacy 4-pyridones, selective inhibitors P. cytochrome bc1.
The concept of "accelerated" chronic lymphocytic leukemia is frequently used by both pathologists and clinicians. However, neither histological criteria to define this form nor its clinical correlates prognostic impact have been formally defined in large series patients.Tissue biopsies from 100 patients with were analyzed for the size proliferation centers their rate as assessed mitosis count Ki-67 immunostaining. Histological patterns correlated main clinico-biological features outcome.A...
To define the clinical and pathologic characteristics of primary cutaneous small/medium CD4(+) T-cell lymphoma (PCSM-TCL) identify parameters prognostic significance.We have investigated 24 patients with lymphomas composed mature T-cells a betaF1, CD3, and/or noncytotoxic, CD8(-) CD30(-) phenotype. The proliferation index CD8(+) infiltrating cells were quantified an automated image analysis system.Sixteen presenting solitary or localized plaques small nodules (< 3 cm) had indolent course....
γδ T cells represent a minor T-cell subset that is mainly distributed in mucosal surfaces. Two distinct lymphomas derived from these have been recognized: hepatosplenic lymphoma (HSTL) and primary cutaneous (PCGD-TCL). However, whether other anatomic sites may also be involved they spectrum of the same disease are not well studied. The lack receptor (TCR)β expression has used to infer origin when methods available. We studied 35 tumors suspected TCL using monoclonal antibodies reactive with...
A retrospective study was performed to assess the outcome of patients with diffuse large B cell lymphoma (DLBCL) who did not achieve complete response or relapsed before and after use rituximab. Clinical features 816 (425 M/391 F; median age 63 years) diagnosed from 1991 2001 (pre-rituximab era, N = 348) 2002 2012 (rituximab 468) in a single institution were evaluated. Five hundred fifty-three achieved remission (CR), 57 partial (PR), 206 refractory overall survival 15, 1.5, 0.4 years,...